With low‑density lipoprotein cholesterol of 3.03 mmol/L, high‑density lipoprotein cholesterol of 1.34 mmol/L, and lipoprotein(a) of 172 nmol/L, what investigations should be undertaken?

Immediate Investigation and Management for Elevated Lipoprotein(a)

Measure Lp(a) once more to confirm the elevation (172 nmol/L is above the 75 nmol/L threshold), then immediately assess for familial hypercholesterolemia (FH), screen first-degree relatives, evaluate for subclinical atherosclerosis with coronary artery calcium scoring or carotid ultrasound, and aggressively lower LDL-C to compensate for the Lp(a)-mediated residual risk that cannot currently be directly treated. 1, 2

Why This Lp(a) Level Matters

Your Lp(a) of 172 nmol/L substantially exceeds both the traditional risk threshold of 75 nmol/L and the European threshold of 100-125 nmol/L for significant cardiovascular risk 1, 2. This represents a genetically-determined, lifelong risk factor that:

• Increases atherosclerotic cardiovascular disease (ASCVD) risk independent of your LDL-C level
• Cannot be modified by diet, exercise, or most current medications
• Warrants one-time measurement but lifetime consideration in risk stratification 1, 3

Critical Investigations to Perform Now

1. Rule Out Familial Hypercholesterolemia

• Your LDL-C of 3.03 mmol/L (~117 mg/dL) combined with elevated Lp(a) raises concern for FH
• FH patients have both elevated lifetime ASCVD risk AND higher Lp(a) levels that synergistically increase risk 1, 4
• Calculate Dutch Lipid Clinic Network score or use Simon Broome criteria
• Consider genetic testing for LDLR, APOB, or PCSK9 mutations 4

Critical pitfall: Elevated Lp(a) itself can lead to clinical misdiagnosis as FH because Lp(a) cholesterol contributes to measured LDL-C, causing overestimation of true LDL-C by conventional assays 5. Your actual LDL-C may be lower than 3.03 mmol/L.

2. Family Cascade Screening

• Measure Lp(a) in all first-degree relatives once
• Lp(a) levels are 90% genetically determined and remain constant throughout life 6, 3
• Identifying affected family members enables early intervention

3. Assess for Subclinical Atherosclerosis

• Coronary artery calcium (CAC) scoring: Quantifies coronary plaque burden; elevated Lp(a) accelerates calcification 1
• Carotid intima-media thickness or plaque assessment: Lp(a) associates with carotid atherosclerosis 2
• These imaging studies reclassify risk and justify more aggressive LDL-C lowering 1

4. Screen for Calcific Aortic Valve Disease (CAVD)

• Echocardiography to assess aortic valve morphology and function
• Lp(a) is causally linked to aortic stenosis; 1 in 7 cases could be prevented by marked Lp(a) lowering 1
• Even without symptoms, baseline assessment guides future monitoring

5. Comprehensive Cardiovascular Risk Assessment

• Blood pressure measurement
• Hemoglobin A1c or fasting glucose
• High-sensitivity C-reactive protein
• Lipoprotein(a) acts synergistically with other risk factors 3

Treatment Strategy: Aggressive LDL-C Lowering

Since no FDA-approved Lp(a)-specific therapy exists outside of lipoprotein apheresis (reserved for extreme cases with progressive ASCVD), you must compensate by driving LDL-C as low as possible. 3

Therapeutic Approach:

1. High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg)

   • Note: Statins may modestly raise Lp(a) by 10-20% in some patients, but the LDL-C benefit far outweighs this 1, 3

2. Add ezetimibe 10 mg if LDL-C remains above target

   • No significant effect on Lp(a) but further reduces LDL-C 3

3. Consider PCSK9 inhibitor (evolocumab or alirocumab) or inclisiran

   • Reduces LDL-C by 50-60%
   • Secondary benefit: lowers Lp(a) by 20-30%, though this is not the primary mechanism 3
   • Particularly justified if you have FH, established ASCVD, or very high calculated risk

4. Bempedoic acid as alternative or addition

   • No effect on Lp(a) but provides additional LDL-C lowering 3

Target LDL-C Goals:

• If no ASCVD: <1.8 mmol/L (<70 mg/dL) given elevated Lp(a) as risk-enhancing factor 7
• If ASCVD present: <1.4 mmol/L (<55 mg/dL) or even <1.0 mmol/L (<40 mg/dL) for very high risk 7

What NOT to Do

• Avoid niacin: Previously used for Lp(a) lowering but now contraindicated as it does not reduce cardiovascular or all-cause mortality 3
• Don't rely on lifestyle modification: Diet and exercise do not lower Lp(a) 6, 8
• Don't delay treatment: Cumulative LDL-C exposure over time drives ASCVD risk; early intensive therapy is critical 7

Future Considerations

RNA-based therapies (pelacarsen, olpasiran, lepodisiran) are in phase 3 trials and reduce Lp(a) by 80-95% 3. If you meet criteria for clinical trials or when these agents receive approval, you would be an ideal candidate. Until then, lipoprotein apheresis (60-75% Lp(a) reduction) remains the only FDA-approved Lp(a)-specific therapy but is reserved for progressive ASCVD despite maximal medical therapy 3.

Documentation

Request your healthcare system add an ICD-10 code for elevated Lp(a) (currently lacking in the U.S.) to facilitate tracking and research 1. Use generic hypercholesterolemia codes in the interim.